Roche struck a deal with Dualitas that includes $36.5 million upfront and could reach $1 billion total, funding the screening of more than 300,000 novel bispecific antibody combinations. The collaboration targets inflammatory and immunology indications, with Roche seeking next-generation bispecifics via broader combination coverage. The arrangement formalizes Roche’s approach of pairing in-house discovery needs with external screening capacity, aiming to accelerate differentiation. Dualitas will run the screening program, while Roche retains the downstream option to develop resulting candidates. In practical terms, the deal signals sustained investment in high-throughput bispecific discovery as competition grows for immune-oncology and inflammation pipeline differentiation.